Redmile Group LLC Buys 5,970,785 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Redmile Group LLC boosted its stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 1,183.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,475,317 shares of the company’s stock after acquiring an additional 5,970,785 shares during the period. Redmile Group LLC owned 18.52% of RAPT Therapeutics worth $10,231,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RAPT. Picton Mahoney Asset Management boosted its position in shares of RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after purchasing an additional 14,697 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after acquiring an additional 25,130 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of RAPT Therapeutics in the 4th quarter valued at $63,000. Sei Investments Co. bought a new position in RAPT Therapeutics during the fourth quarter worth $64,000. Finally, Barclays PLC boosted its stake in RAPT Therapeutics by 277.2% during the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Trading Up 0.3%

Shares of NASDAQ RAPT opened at $0.75 on Thursday. The business has a 50-day moving average of $1.01 and a 200-day moving average of $1.23. The firm has a market capitalization of $99.24 million, a price-to-earnings ratio of -0.27 and a beta of -0.04. RAPT Therapeutics, Inc. has a 12 month low of $0.73 and a 12 month high of $4.83.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.23. On average, analysts predict that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of RAPT Therapeutics in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $4.00.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.